mRNA vaccine shows promise in pancreatic phase 1

Memorial Sloan Kettering Cancer Center researchers presented updated data at the American Association for Cancer Research annual meeting in April showing that an individualized mRNA vaccine for pancreatic cancer continued to generate long-lived immune responses in a small phase 1 study. The vaccine, autogene cevumeran, is designed from each patient’s tumor mutations and was given after surgery alongside atezolizumab and modified FOLFIRINOX chemotherapy. The early trial involved 16 patients with resected pancreatic ductal adenocarcinoma, one of the deadliest common cancers. Investigators said the findings support a larger randomized study now underway. ### How was this vaccine tailored to each patient? Nature reported in 2023 that autogene cevumeran is built by sequencing an individual patient’s tumor, identifying neoantigens created by tumor-specific mutations, and encoding selected targets into a bespoke mRNA product. The goal is to train T cells to recognize cancer cells that carry those mutations while sparing normal tissue. (pharmacytimes.com) Memorial Sloan Kettering said the phase 1 regimen paired the vaccine with a checkpoint inhibitor, atezolizumab, and later with chemotherapy after surgery. The study tested whether pancreatic tumors, which are often considered immunologically resistant, could still generate a measurable vaccine-driven immune response. (nature.com) ### What did the phase 1 study actually show? The 16-patient trial produced vaccine-induced T-cell responses in 8 patients, according to Memorial Sloan Kettering, Nature and follow-up reports from AACR coverage. Those responses were described as durable, with immune cells still detectable years after treatment in some patients. (mskcc.org) CancerNetwork reported from AACR 2026 that seven of the eight immune responders were still alive four to six years after treatment. NBC News, citing the updated trial results, similarly reported that nearly all patients who responded to the personalized vaccine remained alive six years later. ### Why are researchers focused on the T-cell response? (mskcc.org) AACR said earlier follow-up from this same program found that durable and functional T-cell responses were associated with reduced risk of recurrence in some patients with resectable pancreatic cancer. The updated reporting extends that observation by suggesting the immune response may persist far longer than researchers initially documented. (cancernetwork.com) Nature’s follow-up work on the trial described long-lived CD8-positive T cells after treatment. That matters because pancreatic cancer has historically been difficult to target with immunotherapy, and the study was designed to test whether a personalized vaccine could create immune recognition where little existed before. ### What are the limits of these results? The phase 1 study was small, single-arm and not designed to prove a survival benefit. (aacr.org) CancerNetwork said the apparent survival signal now needs to be tested in a larger trial that can distinguish treatment effect from the favorable outcomes that can sometimes appear in early uncontrolled studies. (nature.com) Pharmacy Times reported the data as promising early evidence, not practice-changing evidence. The patients also received surgery, checkpoint blockade and chemotherapy, which makes it difficult to isolate the vaccine’s contribution without a randomized comparison. ### What happens next in the program? Cancer coverage from Memorial Sloan Kettering and other reports said a global randomized phase 2 trial is now testing autogene cevumeran in a larger group of patients after pancreatic cancer surgery. (cancernetwork.com) BioNTech and Genentech, a member of the Roche Group, are developing the vaccine. (pharmacytimes.com) The next readout will come from that phase 2 study, which is intended to test whether the recurrence and survival patterns seen in the 16-patient phase 1 cohort hold up in a controlled setting with more participants. (cancernetwork.com) (mskcc.org)